Docosanol: A topical antiviral for herpes labialis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2567-2571

  Leung, Daniel T ^a   Sacks, Stephen L ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiviral; Docosanol; Herpes labialis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BEHENYL ALCOHOL; MACROGOL; NON PRESCRIPTION DRUG; NUCLEOSIDE ANALOG; PENCICLOVIR; POLOXAMER; VALACICLOVIR;

ABNORMAL FECES COMPOSITION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CORNEA DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HEALING; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HUMAN; IRIS DISEASE; MUCOSA INFLAMMATION; NONHUMAN; RECURRENT VIRUS INFECTION; SYMPTOMATOLOGY; UNITED STATES; VIRUS INHIBITION;

ADMINISTRATION, TOPICAL; CLINICAL TRIALS; EXPERT TESTIMONY; FATTY ALCOHOLS; HERPES LABIALIS; HERPESVIRUS 1, HUMAN; HUMANS;

EID: 10644268604     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2567     Document Type: Article

References (36)

1. SHIP II, MORRIS AL, DUROCHER RT, BURKETT LW: Recurrent aphthous ulcerations and recurrent herpes labialis in a professional school student population. Oral Surg. Oral Med. Oral Pathol. (1960) 13:1191-1202.
2. YOUNG TB, RIMM EB, D'ALESSIO DJ: Cross-sectional study of recurrent herpes labialis. Prevalence and risk factors. Am. J. Epidemiol (1988) 127:612-625.
3. SPRUANCE SL: Herpes simplex labialis. In: Clinical management of herpes viruses (4th edn). Sacks SL, Straus SE, Whitley RJ, and Griffiths PD (Eds), IOS Press, Amsterdam, The Netherlands (1995):3-42.
4. SIMON CA, VAN MELLE GD, RAMELET AA. Failure of lysine in frequently recurrent herpes simplex infection. Arch. Dermatol. (1985) 121:167-168.
5. SPRUANCE SL, REA TL, THOMING C et al.: Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA (1997) 277:1374-1379.
6. RABORN GW, MCGAW WT, GRACE M, HOULE L: Herpes labialis treatment with acyclovir 5 per cent ointment. J. Can. Dent. Assoc. (1989) 55:135-137.
7. SPRUANCE SL, CRUMPACKER CS: Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit. Am. J. Med. (1982) 73:315-319.
8. SPRUANCE SL, CRUMPACKER CS, SCHNIPPER LE et al.: Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob. Agents Chemother. (1984) 25:553-555.
9. FREEMAN DJ, SHETH NV, SPRUANCE SL: Failure of topical acyclovir in ointment to penetrate human skin. Antimicrob. Agents Chemother. (1986) 29: 730-732.
10. BIAGIONI PA, LAMEY PJ: Acyclovir cream prevents clinical and thermographic progression of recrudescent herpes labialis beyond the prodromal stage. Acta Derm. Venereol. (1998) 78:46-47.
11. FIDDIAN AP, IVANYI L: Topical acyclovir in the management of recurrent herpes labialis. Br. J. Dermatol. (1983) 109 321-326.
12. GIBSON JR, KLABER MR, HARVEY SG et al.: Prophylaxis against herpes labialis with acyclovir cream-a placebo-controlled study. Dermatologica (1986) 172:104-107.
13. RABORN GW. MCGAW WT, GRACE M, PERCY J, SAMUELS S: Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind randomized trial. Oral Surg. Oral Med. Oral Pathol. (1989) 67:676-679.
14. RABORN GW, MARTEL AY, GRACE MG, MCGAW WT. Herpes labialis in skiers: randomized clinical trial of acyclovir cream versus placebo. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (1997) 84 641-645.
15. SHAW M, KING M, BEST JM et al.: Failure of acyclovir cream in treatment of recurrent herpes labialis. Br. Med J. (Clin. Res. Ed.) (1985) 291:7-9.
16. SPRUANCE SL, NETT R, MARBURY T et al.: Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob. Agents Chemother. (2002) 46:2238-2243.
17. RABORN GW, MCGAW WT, GRACE M, TYRRELL LD, SAMUELS SM: Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J. Am. Dent. Assoc. (1987) 115 38-42.
18. SPRUANCE SL, HAMILL ML, HOGE WS, DAVIS LG, MILLS J: Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA (1988) 260:1597-1599.
19. SPRUANCE SL, STEWART JC, ROWE NH et al.: Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis. (1990) 161:185-190.
20. RABORN GW, MARTEL AY, GRACE MG, MCGAW WT: Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multi-centered clinical trial. Oral Surg. Oral Med. Oral Pathol. Oral Radiol, Endod. (1998) 85:55-59.
21. SPRUANCE SL, JONES TM, BLATTER MM et al.: High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemotber. (2003) 47:1072-1080.
22. KATZ DH, MARCELLETTI JF, KHALIL MH, POPE LE, KATZ LR: Antiviral Activity of 1-Docosanol, An Inhibitor of Lipid-Enveloped Viruses Including Herpes-Simplex. Proc. Natl. Acad Sci. USA (1991) 88:10825-10829.
23. POPE LE, MARCELLETTI JF, KATZ LR et al.: The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res. (1998) 40:85-94.
24. POPE LE, MARCELLETTI JF, KATZ LR, KATZ DH: Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug. J. Lipid Res. (1996) 37 2167-2178.
25. KHALIL MH, MARCELLETTI JF, KATZ LR, KATZ DH, POPE LE: Topical application of docosanol- or stearic acid-containing creams reduces severity of phenol burn wounds in mice. Contact Dermatitis (2000) 43:79-81.
26. MARCELLETTI JF: Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs. Antiviral Res. (2002) 56:153-166.
27. JOHNSON W. Final report of the safety assessment of cetearyl alcohol, cetyl alcohol, isostearyl alcohol, myristyl alcohol, and behenyl alcohol. J. Am. Coll. Toxicol. (1988) 7:359-413.
28. IGLESIAS G, HLYWKA JJ, BERG JE et al.: The toxicity of behenyl alcohol. I. Genotoxicity and subchronic toxicity in rats and dogs. Regul. Toxical. Pharmacol. (2002) 36:69-79.
29. IGLESIAS G, HLYWKA JJ, BERG JE et al.: The toxicity of behenyl alcohol. II. Reproduction studies in rats and rabbits. Regul. Toxicol. Pharmacol. (2002) 36:80-85.
30. KATZ DH, MARCELLETTI JF, POPE LE et al.: N-docosanol - broad-spectrum antiviral activity against lipid-enveloped viruses. Ann. NY Acad Sci. (1994) 724:472-488.
31. MCKEOUGH AB, SPRUANCE SL: Comparison of new topical treatments for herpes labialis - efficacy of penciclovir cream, acyclovir cream, and n-docosanot cream against experimental cutaneous herpes simplex virus Type I infection. Arch. Dermatol. (2001) 137 1153-1158.
32. HABBEMA L, DEBOULLE K, RODERS GA, KATZ DH: N-docosanol 10% cream in the treatment of recurrent herpes labialis: A randomised, double-blind, placebo-controlled study. Acta Derm. Venereol. (1996) 76:479-481.
33. ANON: Topical lidakol Phase III trials for oral HSV fail to show efficacy versus placebo. Antiviral Agents Bulletin (1996) 9 104-105.
34. SPRUANCE SL: N-docosanol (Abreva) for herpes labialis: Problems and questions. J. Am. Acad. Dermatol. (2002) 47 457-458.
35. SACKS SL, THISTED RA, JONES TM et al.: Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. (2001) 45:222-230.
36. SCOLARO MJ, GUNNILL LB, POPE LE et al.: The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIV Type 1-Infected patients: a pilot clinical study. AIDS Res. Hum. Retroviruses (2001) 17:3543.